🏛️ Verified NIH Record • Updated 2026-07-09

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib (NCT04764188)

A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)

🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Hoffmann-La Roche

🩺 Plain-English Summary (8th-Grade Level)

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (4 items).

Location: Clinica Adventista Belgrano — Ciudad Autonoma Buenos Aires

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria
  • Participants not receiving alectinib for the treatment of ALK-positive advanced NSCLC according to standard of care and in line with local product information
  • Participants not receiving the Roche studied medicinal product
  • Participants who have received or are currently receiving alectinib as an investigational study drug in a clinical trial for the treatment of advanced NSCLC

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (116 Sites)

Showing the first 25 of 116 sites.

  • Clinica Adventista Belgrano — Ciudad Autonoma Buenos Aires,
  • Lifehouse — Camperdown, New South Wales
  • Liverpool Hospital — Liverpool, New South Wales
  • Royal North Shore Hospital — St Leonards, New South Wales
  • GenesisCare North Shore — St Leonards, New South Wales
  • Flinders Medical Centre — Bedford Park, South Australia
  • Peter MacCallum Cancer Center — East Melbourne, Victoria
  • Klinikum Klagenfurt am Wörtersee — Klagenfurt,
  • Klinik Penzing — Vienna,
  • Krankenhaus Nord - Klinik Floridsdorf — Vienna,
  • CHIREC — Auderghem,
  • AZ Sint Lucas (Sint Lucas) — Ghent,
  • Jessa Zkh (Campus Virga Jesse) — Hasselt,
  • AZ Groeninge — Kortrijk,
  • CHU de Liège — Liège,
  • AZ Glorieux- vzw Werken Glorieux — Ronse,
  • Vitaz — Sint-Niklaas,
  • Complex Oncology Center Burgas — Burgas,
  • Multiprofile Hospital for Active Treatment Uni Hospital — Panagyurishte,
  • DDODIU-Plovdiv, EOOD — Plovdiv,
  • MBAL Serdika EOOD — Sofia,
  • Acibadem City Clinic Tokuda — Sofia,
  • Inst. Nacional Del Torax — Santiago, Santiago Metropolitan
  • Centro de Estudios Clínicos SAGA — Santiago,
  • Hu Nan Provincial Cancer Hospital — Changsha,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in NSCLC

Explore by condition: All NSCLC clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗